Trametinib
Detailed Description
A MEK inhibitor that suppresses MEK1 and MEK2 with IC50 of 0.92 and 1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. It has been approved by FDA, in combination with Tafilnar, for the treatment of metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation.https://www.bocsci.com/trametinib-cas-871700-17-3-item-84-307744.html
- Trametinib
View Contact Detail